35.172.230.21
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Growth Hormone Deficiency

Study highlights an oral treatment option for growth hormone deficiency

Posted on

At the Pediatric Endocrine Society 2024 Annual Meeting, a study showed that oral ibutamoren improved height in pediatric patients with growth hormone deficiency (GHD), potentially offering a novel treatment administration for this population.

A total of 81 treatment-naïve children with moderate pediatric GHD were randomized to receive ibutamoren 0.8 mg/kg, 1.6 mg/kg, or 3.2 mg/kg versus recombinant human growth hormone 34 µg/kg once daily for 2 years.

At 1 year, the annualized height velocity in the ibutamoren cohorts was:

  • 8 cm per year in the 1.6 mg/kg group
  • 8 cm per year in the 0.8 mg/kg group
  • 3 cm per year in the 3.2 mg/kg group

Findings in the 1.6 mg/kg ibutamoren cohort were deemed “comparable” to the annualized height velocity of 9.7 cm per year observed with recombinant human growth hormone.

The researchers reported no serious adverse events associated with ibutamoren.

Reference

Dauber A, et al. Oral LUM-201 shows similar annualized height velocity to daily rhGH in moderate pediatric growth hormone deficiency (PGHD) with a 1.6 mg/kg/day dose and a promising investigational safety record. Presented at the Pediatric Endocrine Society Annual Meeting, May 2-5, 2024, Chicago, Illinois.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-